Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.

Nelson J, Roe K, Orillo B, Shi PY, Verma S. Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Res. 2015 Oct; 122:39-45.

View in: PubMed

subject areas

Adenosine
Animals
Brain
Chemokine CCL3
Drug Therapy, Combination
Histone Deacetylase Inhibitors
Hydroxamic Acids
Mice
Tumor Necrosis Factor-alpha
Vero Cells
Virus Replication
West Nile Fever
West Nile virus

authors with profiles

Saguna Verma, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support